Protocol Ledger

NCT03606967 · Phase II · RECRUITING

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

Interventional Phase II clinical trial protocol NCT03606967 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-04-13 Enrollment: 86 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03606967
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)86 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03606967
Protocol FieldVerified Registry Value
NCT IdentifierNCT03606967
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment86 participants (ESTIMATED)
Registered Start Date2021-04-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI